Article thumbnail

Isolation of a Human Anti-HIV gp41 Membrane Proximal Region Neutralizing Antibody by Antigen-Specific Single B Cell Sorting

By Lynn Morris, Xi Chen, Munir Alam, Georgia Tomaras, Ruijun Zhang, Dawn J. Marshall, Bing Chen, Robert Parks, Andrew Foulger, Frederick Jaeger, Michele Donathan, Mira Bilska, Elin S. Gray, Salim S. Abdool Karim, Thomas B. Kepler, John Whitesides, David Montefiori, M. Anthony Moody, Hua-Xin Liao and Barton F. Haynes


Broadly neutralizing antibodies are not commonly produced in HIV-1 infected individuals nor by experimental HIV-1 vaccines. When these antibodies do occur, it is important to be able to isolate and characterize them to provide clues for vaccine design. CAP206 is a South African subtype C HIV-1-infected individual previously shown to have broadly neutralizing plasma antibodies targeting the envelope gp41 distal membrane proximal external region (MPER). We have now used a fluoresceinated peptide tetramer antigen with specific cell sorting to isolate a human neutralizing monoclonal antibody (mAb) against the HIV-1 envelope gp41 MPER. The isolated recombinant mAb, CAP206-CH12, utilized a portion of the distal MPER (HXB2 amino acid residues, 673–680) and neutralized a subset of HIV-1 pseudoviruses sensitive to CAP206 plasma antibodies. Interestingly, this mAb was polyreactive and used the same germ-line variable heavy (VH1-69) and variable kappa light chain (VK3-20) gene families as the prototype broadly neutralizing anti-MPER mAb, 4E10 (residues 672–680). These data indicate that there are multiple immunogenic targets in the C-terminus of the MPER of HIV-1 gp41 envelope and suggests that gp41 neutralizing epitopes may interact with a restricted set of naive B cells during HIV-1 infection

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2009). A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies.
  2. (1993). A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.
  3. (2008). A fusionintermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies.
  4. (2006). A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses.
  5. (2005). A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope.
  6. (1991). A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals.
  7. (2007). An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10.
  8. (2005). Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.
  9. (2010). Antigp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity.
  10. (2010). Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions.
  11. Balla u nC ,B u c h a c h e rA ,e ta l
  12. (2009). Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.
  13. (2009). Broad diversity of neutralizing antibodies isolated from memory B cells in HIVinfected individuals.
  14. (2009). Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region.
  15. (2005). Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41.
  16. (2001). Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.
  17. (2005). Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.
  18. (2004). Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody.
  19. (2010). Crystal structure and size-dependent neutralization properties of HK20, a human monoclonal antibody binding to the highly conserved heptad repeat 1 of gp41. PLoS
  20. (2010). Crystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane-proximal external region.
  21. (2008). Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning.
  22. (2008). Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study.
  23. (2009). Functional, non-clonal IgMa-restricted B cell receptor interactions with the HIV-1 envelope gp41 membrane proximal external region.
  24. (2006). Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa.
  25. (2009). Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens.
  26. (2009). Highthroughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies.
  27. (2008). HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane.
  28. (2007). HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry.
  29. (2005). Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.
  30. (2008). Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection.
  31. (1997). Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features.
  32. (2010). Induction of immunity to human immunodeficiency virus type-1 by vaccination.
  33. (2008). Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia.
  34. (2006). Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B.
  35. (2010). Interactions between lipids and human anti-HIV antibody 4E10 can be reduced without ablating neutralizing activity.
  36. (2007). Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection.
  37. (2010). Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation.
  38. (2009). Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1.
  39. (2010). Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.
  40. (2009). Role of HIV membrane in neutralization by two broadly neutralizing antibodies.
  41. (2006). Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.
  42. (2006). SoDA: implementation of a 3D alignment algorithm for inference of antigen receptor recombinations.
  43. (2009). Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is HIV-1
  44. (1987). Standardising the anti-cardiolipin antibody test.
  45. (2009). Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses.
  46. (2003). Studies of human polyclonal and monoclonal antibodies binding to lupus autoantigens and cross-reactive antigens. Rheumatology (Oxford)
  47. (2005). The membrane-proximal external region of HIV-1 gp41: a vaccine target worth exploring.
  48. (2007). The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes.
  49. (2009). Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41.